Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in Geographic Atrophy Secondary to Age-Related Macular Degeneration
NCT07174687Phase 2Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in geographic atrophy (GA) comparing Dapagliflozin 10 mg with Placebo (2 arms). Primary endpoint: Mean Change From Baseline in Square Root GA Lesion Size at 12 months. Started Dec 2025; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
geographic atrophy (GA)
Beyond the preview
Go deeper on NCT07174687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07174687.